HomeCompareSLVMF vs PFE

SLVMF vs PFE: Dividend Comparison 2026

SLVMF yields 1349.53% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SLVMF wins by $269284839.68M in total portfolio value
10 years
SLVMF
SLVMF
● Live price
1349.53%
Share price
$0.15
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$269284839.73M
Annual income
$235,026,052,065,859.03
Full SLVMF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — SLVMF vs PFE

📍 SLVMF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSLVMFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SLVMF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SLVMF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SLVMF
Annual income on $10K today (after 15% tax)
$114,709.85/yr
After 10yr DRIP, annual income (after tax)
$199,772,144,255,980.16/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, SLVMF beats the other by $199,772,144,233,660.25/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SLVMF + PFE for your $10,000?

SLVMF: 50%PFE: 50%
100% PFE50/50100% SLVMF
Portfolio after 10yr
$134642419.89M
Annual income
$117,513,026,046,058.88/yr
Blended yield
87.28%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

SLVMF
No analyst data
Altman Z
82.5
Piotroski
3/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SLVMF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSLVMFPFE
Forward yield1349.53%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$269284839.73M$49.6K
Annual income after 10y$235,026,052,065,859.03$26,258.71
Total dividends collected$266763063.23M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SLVMF vs PFE ($10,000, DRIP)

YearSLVMF PortfolioSLVMF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$145,653$134,952.77$9,153$693.39+$136.5KSLVMF
2$1,992,881$1,837,032.13$8,593$849.25+$1.98MSLVMF
3$25,623,058$23,490,675.96$8,336$1,066.78+$25.61MSLVMF
4$309,684,527$282,267,854.29$8,437$1,384.80+$309.68MSLVMF
5$3,519,713,895$3,188,351,451.47$9,013$1,875.40+$3519.70MSLVMF
6$37,632,589,992$33,866,496,124.05$10,306$2,680.72+$37632.58MSLVMF
7$378,676,907,768$338,410,036,477.29$12,820$4,101.38+$378676.89MSLVMF
8$3,587,653,205,892$3,182,468,914,579.67$17,673$6,826.70+$3587653.19MSLVMF
9$32,017,558,563,920$28,178,769,633,615.88$27,543$12,591.86+$32017558.54MSLVMF
10$269,284,839,729,253$235,026,052,065,859.03$49,560$26,258.71+$269284839.68MSLVMF

SLVMF vs PFE: Complete Analysis 2026

SLVMFStock

Silver Mines Limited primarily engages in the acquisition, exploration, and development of silver projects in Australia. It operates through two segments, Mining and Exploration Operations, and Agricultural Operations. The company also explores for copper, gold, lead, zinc, and polymetallic deposits. Its properties include Bowdens Silver Project, which has silver and polymetallic prospects covering an area of 1,950 square kilometers located in the Central Tablelands Region, New South Wales; the Barabolar Project consists of copper, gold, and silver prospects located in the Macquarie Arc in New South Wales; and Tuena Project with gold and silver prospects, which is located 80 kilometers south of the city of Orange in New South Wales. Silver Mines Limited was incorporated in 2004 and is based in Sydney, Australia.

Full SLVMF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this SLVMF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SLVMF vs SCHDSLVMF vs JEPISLVMF vs OSLVMF vs KOSLVMF vs MAINSLVMF vs JNJSLVMF vs MRKSLVMF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.